Carisma Therapeutics IncNASDAQ:CARM
- LAST PRICE1.1500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.1000/ 26
- Ask / Lots1.1500/ 3
- Open / Previous Close0.0000 / 1.1500
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CARM |
|---|---|---|
| 09:32 ET | 35813 | 1.1 |
| 09:34 ET | 11462 | 1.08 |
| 09:36 ET | 3376 | 1.1 |
| 09:38 ET | 8482 | 1.05 |
| 09:39 ET | 100 | 1.0736 |
| 09:43 ET | 2836 | 1.06 |
| 09:48 ET | 27746 | 1.04 |
| 09:50 ET | 3084 | 1.05 |
| 09:52 ET | 938 | 1.055 |
| 09:54 ET | 500 | 1.0597 |
| 09:56 ET | 444 | 1.05 |
| 09:57 ET | 200 | 1.055 |
| 09:59 ET | 19746 | 1.0599 |
| 10:01 ET | 7032 | 1.0838 |
| 10:03 ET | 2977 | 1.08 |
| 10:06 ET | 800 | 1.085 |
| 10:08 ET | 10300 | 1.085 |
| 10:10 ET | 11583 | 1.11 |
| 10:12 ET | 600 | 1.11 |
| 10:14 ET | 4000 | 1.11 |
| 10:15 ET | 5510 | 1.115 |
| 10:17 ET | 753 | 1.1196 |
| 10:19 ET | 8662 | 1.12 |
| 10:21 ET | 3473 | 1.13 |
| 10:24 ET | 1946 | 1.1499 |
| 10:26 ET | 950 | 1.145 |
| 10:28 ET | 200 | 1.15 |
| 10:30 ET | 5277 | 1.16 |
| 10:32 ET | 13538 | 1.12 |
| 10:33 ET | 29008 | 1.095 |
| 10:35 ET | 300 | 1.1055 |
| 10:39 ET | 2000 | 1.09 |
| 10:42 ET | 500 | 1.09 |
| 10:44 ET | 15100 | 1.11 |
| 10:46 ET | 100 | 1.1 |
| 10:48 ET | 3000 | 1.11 |
| 10:51 ET | 100 | 1.12 |
| 10:53 ET | 200 | 1.12 |
| 10:55 ET | 695 | 1.115 |
| 11:00 ET | 10457 | 1.13 |
| 11:04 ET | 1356 | 1.135 |
| 11:06 ET | 100 | 1.14 |
| 11:08 ET | 140 | 1.1344 |
| 11:09 ET | 300 | 1.14 |
| 11:13 ET | 400 | 1.135 |
| 11:18 ET | 328 | 1.1304 |
| 11:20 ET | 1963 | 1.13 |
| 11:27 ET | 128 | 1.13 |
| 11:31 ET | 168 | 1.1296 |
| 11:36 ET | 7237 | 1.12 |
| 11:40 ET | 268 | 1.1204 |
| 11:42 ET | 28770 | 1.12 |
| 11:44 ET | 1331 | 1.12 |
| 11:45 ET | 3600 | 1.15 |
| 11:47 ET | 2669 | 1.145 |
| 11:49 ET | 5224 | 1.1699 |
| 11:51 ET | 22075 | 1.14 |
| 11:54 ET | 2000 | 1.155 |
| 11:56 ET | 6540 | 1.155 |
| 12:00 ET | 200 | 1.16 |
| 12:02 ET | 200 | 1.155 |
| 12:03 ET | 29128 | 1.13 |
| 12:05 ET | 1500 | 1.135 |
| 12:07 ET | 9292 | 1.13 |
| 12:09 ET | 5150 | 1.13 |
| 12:12 ET | 300 | 1.13 |
| 12:14 ET | 100 | 1.135 |
| 12:20 ET | 929 | 1.1396 |
| 12:23 ET | 275 | 1.135 |
| 12:30 ET | 2550 | 1.135 |
| 12:32 ET | 220 | 1.14 |
| 12:38 ET | 400 | 1.14 |
| 12:39 ET | 1107 | 1.15 |
| 12:41 ET | 2561 | 1.155 |
| 12:43 ET | 200 | 1.155 |
| 12:45 ET | 1000 | 1.155 |
| 12:48 ET | 100 | 1.155 |
| 12:52 ET | 200 | 1.1551 |
| 12:54 ET | 100 | 1.1596 |
| 12:56 ET | 200 | 1.155 |
| 12:57 ET | 1000 | 1.155 |
| 12:59 ET | 826 | 1.1501 |
| 01:03 ET | 2200 | 1.15 |
| 01:06 ET | 711 | 1.155 |
| 01:10 ET | 1300 | 1.155 |
| 01:12 ET | 1205 | 1.1521 |
| 01:21 ET | 100 | 1.155 |
| 01:26 ET | 6130 | 1.14 |
| 01:28 ET | 1100 | 1.1496 |
| 01:39 ET | 550 | 1.15 |
| 01:42 ET | 665 | 1.1496 |
| 01:44 ET | 2743 | 1.13 |
| 01:46 ET | 1585 | 1.13 |
| 01:53 ET | 1202 | 1.12 |
| 01:55 ET | 200 | 1.1205 |
| 01:57 ET | 1506 | 1.12 |
| 02:02 ET | 2139 | 1.11 |
| 02:04 ET | 1477 | 1.1031 |
| 02:06 ET | 1753 | 1.1 |
| 02:18 ET | 700 | 1.11 |
| 02:20 ET | 100 | 1.12 |
| 02:33 ET | 781 | 1.11 |
| 02:36 ET | 400 | 1.12 |
| 02:38 ET | 300 | 1.12 |
| 02:40 ET | 1282 | 1.12 |
| 02:42 ET | 1450 | 1.115 |
| 02:44 ET | 600 | 1.12 |
| 02:45 ET | 200 | 1.12 |
| 02:47 ET | 906 | 1.115 |
| 02:49 ET | 500 | 1.12 |
| 02:51 ET | 500 | 1.115 |
| 02:54 ET | 400 | 1.12 |
| 02:56 ET | 600 | 1.12 |
| 02:58 ET | 100 | 1.12 |
| 03:00 ET | 300 | 1.12 |
| 03:02 ET | 500 | 1.13 |
| 03:03 ET | 724 | 1.13 |
| 03:05 ET | 605 | 1.13 |
| 03:07 ET | 558 | 1.13 |
| 03:09 ET | 500 | 1.13 |
| 03:12 ET | 956 | 1.13 |
| 03:14 ET | 700 | 1.12 |
| 03:16 ET | 500 | 1.12 |
| 03:18 ET | 1039 | 1.115 |
| 03:20 ET | 100 | 1.115 |
| 03:21 ET | 400 | 1.13 |
| 03:23 ET | 600 | 1.13 |
| 03:25 ET | 823 | 1.12 |
| 03:27 ET | 2237 | 1.13 |
| 03:30 ET | 1643 | 1.12 |
| 03:32 ET | 500 | 1.13 |
| 03:34 ET | 1100 | 1.13 |
| 03:36 ET | 4813 | 1.115 |
| 03:38 ET | 100 | 1.115 |
| 03:39 ET | 1700 | 1.115 |
| 03:41 ET | 1939 | 1.115 |
| 03:43 ET | 2000 | 1.12 |
| 03:45 ET | 5020 | 1.12 |
| 03:48 ET | 2724 | 1.13 |
| 03:50 ET | 1200 | 1.13 |
| 03:52 ET | 8224 | 1.12 |
| 03:54 ET | 618 | 1.12 |
| 03:56 ET | 4198 | 1.12 |
| 03:57 ET | 5652 | 1.125 |
| 03:59 ET | 7526 | 1.15 |
Yesterday
Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum, from 21 hours ago by Dow Jones
21 hours ago by Dow JonesCarisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors, from 21 hours ago by Dow Jones
21 hours ago by Dow Jones
Jun 13, 2024
Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders, from 4:30PM ET on Thursday Jun 13, 2024 by Dow Jones
4:30PM ET on Thursday Jun 13, 2024 by Dow Jones
May 30, 2024
Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference, from 7:30AM ET on Thursday May 30, 2024 by Dow Jones
7:30AM ET on Thursday May 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Carisma Therapeutics Inc | 47.8M | -0.6x | --- |
Aligos Therapeutics Inc | 31.5M | -0.3x | --- |
ImmuCell Corp | 35.3M | -9.0x | --- |
Eiger BioPharmaceuticals Inc | 19.3M | -0.3x | --- |
Curis Inc | 46.2M | -0.9x | --- |
Collplant Biotechnologies Ltd | 58.4M | -7.6x | --- |
Company Information
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.
Contact Information
- Headquarters
- 245 1st St Ste 1800CAMBRIDGE, MA, United States 02142-1292
- Phone
- 617-444-8550
- Fax
- 617-858-0911
Executives
- Independent Non-Executive Chairman of the Board
- Sanford Zweifach
- President, Chief Executive Officer, Director
- Steven Kelly
- Chief Financial Officer
- Richard Morris
- Chief Scientific Officer
- Michael Klichinsky
- General Counsel, Corporate Secretary
- Eric Siegel
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $47.8M |
|---|---|
Revenue (TTM) | $15.1M |
Shares Outstanding | 41.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.52 |
EPS | $-2.01 |
Book Value | $0.65 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | 3.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -565.71% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
